Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Preventing microalbuminuria with benazepril, valsartan, and benazepril-valsartan combination therapy in diabetic patients with high-normal albuminuria: A prospective, randomized, open-label, blinded endpoint (PROBE) study.
Ruggenenti P, Cortinovis M, Parvanova A, Trillini M, Iliev IP, Bossi AC, Belviso A, Aparicio MC, Trevisan R, Rota S, Perna A, Peracchi T, Rubis N, Martinetti D, Prandini S, Gaspari F, Carrara F, De Cosmo S, Tonolo G, Mangili R, Remuzzi G; VARIETY Study Organization. Ruggenenti P, et al. Among authors: aparicio mc. PLoS Med. 2021 Jul 14;18(7):e1003691. doi: 10.1371/journal.pmed.1003691. eCollection 2021 Jul. PLoS Med. 2021. PMID: 34260595 Free PMC article. Clinical Trial.
Effects of valsartan, benazepril and their combination in overt nephropathy of type 2 diabetes: A prospective, randomized, controlled trial.
Ruggenenti P, Trillini M, P Barlovic D, Cortinovis M, Pisani A, Parvanova A, Iliev IP, Ruggiero B, Rota S, Aparicio MC, Perna A, Peraro F, Diadei O, Gaspari F, Carrara F, Stucchi N, Martinetti D, Janez A, Gregoric N, Riccio E, Bossi AC, Trevisan R, Manunta P, Battaglia G, David S, Aucella F, Belviso A, Satta A, Remuzzi G; VALID Study Organization. Ruggenenti P, et al. Among authors: aparicio mc. Diabetes Obes Metab. 2019 May;21(5):1177-1190. doi: 10.1111/dom.13639. Epub 2019 Feb 22. Diabetes Obes Metab. 2019. PMID: 30793466 Clinical Trial.
Effect of Sirolimus on Disease Progression in Patients with Autosomal Dominant Polycystic Kidney Disease and CKD Stages 3b-4.
Ruggenenti P, Gentile G, Perico N, Perna A, Barcella L, Trillini M, Cortinovis M, Ferrer Siles CP, Reyes Loaeza JA, Aparicio MC, Fasolini G, Gaspari F, Martinetti D, Carrara F, Rubis N, Prandini S, Caroli A, Sharma K, Antiga L, Remuzzi A, Remuzzi G; SIRENA 2 Study Group. Ruggenenti P, et al. Among authors: aparicio mc. Clin J Am Soc Nephrol. 2016 May 6;11(5):785-794. doi: 10.2215/CJN.09900915. Epub 2016 Feb 22. Clin J Am Soc Nephrol. 2016. PMID: 26912555 Free PMC article. Clinical Trial.
Effect of spironolactone wash-out on albuminuria after long-term treatment in individuals with type 2 diabetes and high risk of kidney disease-An observational follow-up of the PRIORITY study.
Wasehuus V, Rotbain Curovic V, Tofte N, Lindhardt M, Currie G, Delles C, Frimodt-Møller M, Mischak H, von der Leyen H, Hansen TW, Kümler T, Persson F, Rossing P; PRIORITY Study group. Wasehuus V, et al. Diabetes Obes Metab. 2025 Jan;27(1):387-393. doi: 10.1111/dom.16037. Epub 2024 Oct 28. Diabetes Obes Metab. 2025. PMID: 39468380 Clinical Trial.
Access to direct-acting antivirals for the treatment of hepatitis C in a country with limited resources.
Marciano S, Haddad L, Borzi SM, D'Amico C, Gaite LA, Aubone MV, Sirotinsky ME, Ratusnu N, Frola MS, Aparicio MC, Ríos B, Anselmo MN, Hansen R, De Filippi S, Dans CG, de Labra L, Peche MA, Strella TM, Ibáñez Duran M, García Rosales MB, Dirchwolf M, Galdame OA, Gadano AC. Marciano S, et al. Among authors: aparicio mc. Rev Gastroenterol Mex (Engl Ed). 2018 Apr-Jun;83(2):208-211. doi: 10.1016/j.rgmx.2018.02.009. Epub 2018 Apr 12. Rev Gastroenterol Mex (Engl Ed). 2018. PMID: 29656845 Free article. English, Spanish.
Moderate salt restriction with or without paricalcitol in type 2 diabetes and losartan-resistant macroalbuminuria (PROCEED): a randomised, double-blind, placebo-controlled, crossover trial.
Parvanova A, Trillini M, Podestà MA, Iliev IP, Ruggiero B, Abbate M, Perna A, Peraro F, Diadei O, Rubis N, Gaspari F, Carrara F, Stucchi N, Belviso A, Bossi AC, Trevisan R, Remuzzi G, de Borst M, Ruggenenti P; PROCEED Study Organization and the Scientific Writing Academy (SWA) 2016. Parvanova A, et al. Lancet Diabetes Endocrinol. 2018 Jan;6(1):27-40. doi: 10.1016/S2213-8587(17)30359-5. Epub 2017 Nov 2. Lancet Diabetes Endocrinol. 2018. PMID: 29104158 Clinical Trial.